Progress Being Made in Getting a Quality Leader in Every School

Reviews the progress made by the SREB states in improving their school leadership through redesigning the process of preparation and development of school principals. Describes promising practices being implemented, and offers practical guidance

Are SREB States Making Progress? Tapping, Preparing and Licensing School Leaders Who Can Influence Student Achievement

Looks at the progress SREB states are making in developing systems to identify, prepare, and assess future school leaders

Black holes die hard: can one spin-up a black hole past extremality?

A possible process to destroy a black hole consists on throwing point particles with sufficiently large angular momentum into the black hole. In the case of Kerr black holes, it was shown by Wald that particles with dangerously large angular momentum are simply not captured by the hole, and thus the event horizon is not destroyed. Here we reconsider this gedanken experiment for a variety of black hole geometries, from black holes in higher dimensions to black rings. We show that this particular way of destroying a black hole does not succeed and that Cosmic Censorship is preserved.Comment: 10 pages, 7 figures. RevTex4

Bayes' Rays: Uncertainty Quantification for Neural Radiance Fields

Neural Radiance Fields (NeRFs) have shown promise in applications like view synthesis and depth estimation, but learning from multiview images faces inherent uncertainties. Current methods to quantify them are either heuristic or computationally demanding. We introduce BayesRays, a post-hoc framework to evaluate uncertainty in any pre-trained NeRF without modifying the training process. Our method establishes a volumetric uncertainty field using spatial perturbations and a Bayesian Laplace approximation. We derive our algorithm statistically and show its superior performance in key metrics and applications. Additional results available at: https://bayesrays.github.io

Symplectic duality of Symmetric Spaces

We show that between symmetric spaces of different types there exists a bi-symplectic map. We compute the duality map explicitely by using the theory of Jordan Algebra

The Grizzly, October 7, 1983

Career Workshops Held • What\u27s in a Name • Fago Opens Lecture Series • Lantern Makes National Anthology • Campus Memo • Letters to the Editor • Red and Gold Days Inaugurated • Sorority Pledging Underway • Half-Price Student Rushes for Genty! • Keep it Clean • Renaissance Play at Ursinus Commemoration • ATO Incident at Penn • Politics Sells Papers • Yearbook Sale Begins Monday • Ursinus Soccer Romps Over Hopkins • Volleyball Scores Second Victory • Grizzlies Fall to Swarthmorehttps://digitalcommons.ursinus.edu/grizzlynews/1103/thumbnail.jp

The Grizzly, October 28, 1983

CampusBooks Speaks Out • C and C Course Offered • Zack Is Back In Bronze • Peace Rally Held • Give Us A Little Bit Of Credit • Respect Is Goal Of Liberal Education • Homecoming: A Big Success • Nobel Prize Awarded • Spirit Week Begins • The Talented Two-Some • The Stone Age is Back • Crown Royal Features Ultimate Competition • Lady Bears Prepare For Penn State Rivalry • U.C. Soccer Continues Winning Ways • Grizziles Roll Over Lebanon Valleyhttps://digitalcommons.ursinus.edu/grizzlynews/1105/thumbnail.jp

Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer's Disease

The A(2A) adenosine receptor is a protein belonging to a family of four GPCR adenosine receptors. It is involved in the regulation of several pathophysiological conditions in both the central nervous system and periphery. In the brain, its localization at pre- and postsynaptic level in striatum, cortex, hippocampus and its effects on glutamate release, microglia and astrocyte activation account for a crucial role in neurodegenerative diseases, including Alzheimer's disease (AD). This ailment is considered the main form of dementia and is expected to exponentially increase in coming years. The pathological tracts of AD include amyloid peptide-beta extracellular accumulation and tau hyperphosphorylation, causing neuronal cell death, cognitive deficit, and memory loss. Interestingly, in vitro and in vivo studies have demonstrated that A(2A) adenosine receptor antagonists may counteract each of these clinical signs, representing an important new strategy to fight a disease for which unfortunately only symptomatic drugs are available. This review offers a brief overview of the biological effects mediated by A(2A) adenosine receptors in AD animal and human studies and reports the state of the art of A(2A) adenosine receptor antagonists currently in clinical trials. As an original approach, it focuses on the crucial role of pharmacokinetics and ability to pass the blood-brain barrier in the discovery of new agents for treating CNS disorders. Considering that A(2A) receptor antagonist istradefylline is already commercially available for Parkinson's disease treatment, if the proof of concept of these ligands in AD is confirmed and reinforced, it will be easier to offer a new hope for AD patients